Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer
Author:
Affiliation:
1. AbbVie Inc.; North Chicago IL USA
2. Alexion Pharmaceuticals, Inc.; Cheshire CT USA
3. UCLA Santa Monica Hematology-Oncology; Santa Monica CA USA
Funder
AbbVie
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcpt.12193/fullpdf
Reference20 articles.
1. Targeting apoptosis proteins in hematological malignancies;Droin;Cancer Lett,2013
2. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy;Tomek;J Pharm Pharmacol,2012
3. Targeting the B-cell lymphoma/leukemia 2 family in cancer;Davids;J Clin Oncol,2012
4. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor;Tse;Cancer Res,2008
5. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity;Wilson;Lancet Oncol,2010
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Clinical advances in TNC delivery vectors and their conjugate agents;Pharmacology & Therapeutics;2024-01
2. Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms;Computational and Structural Biotechnology Journal;2023
3. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy;Journal of Clinical Oncology;2022-05-20
4. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of navitoclax;Biomedical Chromatography;2022-01-07
5. BH3-mimetics: recent developments in cancer therapy;Journal of Experimental & Clinical Cancer Research;2021-11-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3